High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial

• DOI: 10.1371/journal.pone.0306595
• Publication Date: 2024-07-05T17:22:32Z
• Authors: Xiyue Yang; Yao Liao; Lingli Fan; Binwei Lin; Jie Li; Danfeng Wu; Dongbiao Liao; Li Yuan; Jihui Liu; Feng Gao; Gang Feng; Xiaobo Du
• Keywords: High-intensity focused ultrasound; Microwave ablation; Liver Cancer

Purpose Given the unique features of liver, it is necessary to combine immunotherapy with other therapies improve its efficacy in patients advanced cancer liver metastases (LM). High-intensity focused ultrasound (HIFU) ablation now widely used clinical practice and can enhanced immune benefits. The study intended prospectively evaluate safety feasibility HIFU combination systemic for metastases. Methods enrolled 14 LM who received ultrasound-guided combined checkpoint inhibitors (ICIs) such as anti-programmed cell death protein 1 (anti-PD-1 agents manufactured China) at Mianyang Central Hospital. Patients were followed up adverse events (AEs) during trial, using CommonTerminology Criteria Adverse Events v5.0(CTCAE v5.0) standard. Tumour response after treatment was assessed computerized tomography. Results (age range, 35–84 years) underwent 19 metastatic sites immunotherapy. mean lesion volume 179.9 cm3 (maximum: 733.1 cm3). Median follow-up this trial 9 months (range: 3–21) months. clinically feasible acceptable patients. Conclusion This prospective confirmed that safe treating